Immuneering Corporation Payments of Stock Issuance Costs
Immuneering Corporation (IMRX) reported Payments of Stock Issuance Costs of $0 for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Financing Activities
us-gaap:PaymentsOfStockIssuanceCosts · last filed 2026-08-05
- Immuneering Corporation payments of stock issuance costs for the quarter ending 2025-12-31 was $587.36K, a 1332.99% increase year-over-year.
- Immuneering Corporation payments of stock issuance costs for the quarter ending 2025-09-30 was $3.07M.
- Immuneering Corporation payments of stock issuance costs for the quarter ending 2024-12-31 was $40.99K.
- Immuneering Corporation payments of stock issuance costs for the quarter ending 2024-09-30 was $0.00.
- Immuneering Corporation payments of stock issuance costs for fiscal 2025 was $3.73M, a 8991.11% increase from fiscal 2024.
- Immuneering Corporation payments of stock issuance costs for fiscal 2024 was $40.99K, a 79.88% decline from fiscal 2023.
- Immuneering Corporation payments of stock issuance costs for fiscal 2023 was $203.77K, a 27.58% decline from fiscal 2022.
- Immuneering Corporation payments of stock issuance costs for fiscal 2022 was $281.38K, a 86.75% decline from fiscal 2021.
| Period end | Payments of Stock Issuance Costs 3 month | Payments of Stock Issuance Costs 6 month | Payments of Stock Issuance Costs 9 month | Payments of Stock Issuance Costs 12 month |
|---|---|---|---|---|
| 2026-06-30 | $0.00 10-Q · filed 2026-08-05 | |||
| 2025-12-31 | $587.36K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-06 | $3.66M derived: sum of 2 quarters · filed 2026-03-06 | $3.73M 10-K · filed 2026-03-06 | |
| 2025-09-30 | $3.07M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $3.14M 10-Q · filed 2025-11-12 | ||
| 2025-06-30 | $64.01K 10-Q · filed 2026-08-05 | |||
| 2024-12-31 | $40.99K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-06 | $40.99K derived: sum of 2 quarters · filed 2026-03-06 | $40.99K 10-K · filed 2026-03-06 | |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $0.00 10-Q · filed 2025-11-12 | ||
| 2024-06-30 | $0.00 10-Q · filed 2025-08-13 | |||
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-20 | $0.00 derived: sum of 2 quarters · filed 2025-03-20 | $203.77K 10-K · filed 2025-03-20 | |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | $203.77K 10-Q · filed 2024-11-13 | ||
| 2023-06-30 | $203.77K 10-Q · filed 2024-08-06 | |||
| 2022-12-31 | $226.78K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-01 | $281.38K derived: sum of 2 quarters · filed 2024-03-01 | $281.38K 10-K · filed 2024-03-01 | |
| 2022-09-30 | $54.60K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $54.60K 10-Q · filed 2023-11-09 | ||
| 2022-06-30 | $0.00 10-Q · filed 2023-08-03 | |||
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-10 | $2.12M 10-K · filed 2022-03-10 | ||
| 2021-09-30 | $2.12M 10-Q · filed 2021-11-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Quantum Cyber N.V. (QUCY) | $0.113B | ||
| BICYCLE THERAPEUTICS PLC (BCYC) | $0.112B | -1.56 | |
| GENELUX Corp (GNLX) | United States | $0.110B | -3.83 |
| Equillium, Inc. (EQ) | United States | $0.109B | -11.27 |
| OnKure Therapeutics, Inc. (OKUR) | United States | $0.119B | -3.13 |
| Biomea Fusion, Inc. (BMEA) | United States | $0.107B | -3.30 |
| Polaryx Therapeutics, Inc. (PLYX) | United States | $0.106B | |
| Coya Therapeutics, Inc. (COYA) | United States | $0.121B | -6.35 |
| CUMBERLAND PHARMACEUTICALS INC (CPIX) | United States | $0.121B | -8.95 |
| Aardvark Therapeutics, Inc. (AARD) | United States | $0.121B | -1.80 |